HDL cholesterol efflux predicts graft failure in renal transplant recipients

Journal of the American Society of Nephrology

Volumn 27, Issue 2, 2016, Pages 595-603

  Annema, Wijtske ^a,b   DIkkers, Arne ^a   De Boer, Jan Freark ^a   Dullaart, Robin P F ^a   Sanders, Jan Stephan F ^a   Bakker, Stephan J L ^a   Tietge, Uwe J F ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b TOP INSTITUTE FOOD AND NUTRITION   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ALL CAUSE MORTALITY; ARTICLE; CARDIOVASCULAR MORTALITY; CHOLESTEROL TRANSPORT; CREATININE CLEARANCE; FEMALE; GRAFT FAILURE; HUMAN; HUMAN CELL; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; BLOOD; FOAM CELL; METABOLISM; MIDDLE AGED; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT FAILURE;

BIOLOGICAL TRANSPORT; CHOLESTEROL, HDL; FEMALE; FOAM CELLS; HUMANS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 84970938018     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2014090857     Document Type: Article

References (48)

1. Assmann G, Schulte H, von Eckardstein A, Huang Y: High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 124[Suppl]: S11-S20, 1996
2. Castelli WP, Garrison RJ, Wilson PW, Abbott RD, Kalousdian S, Kannel WB: Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 256: 2835-2838, 1986
3. Corsetti JP, Zareba W, Moss AJ, Rainwater DL, Sparks CE: Elevated HDL is a risk factor for recurrent coronary events in a subgroup of nondiabetic postinfarction patients with hypercholesterolemia and inflammation. Atherosclerosis 187: 191-197, 2006
4. deGoma EM, deGoma RL, Rader DJ: Beyond high-density lipoprotein cholesterol levels evaluating high-density lipoprotein function as influenced by novel therapeutic approaches. J Am Coll Cardiol 51: 2199-2211, 2008
5. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. NEngl J Med 357: 2109-2122, 2007
6. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K,Weintraub W; AIM-HIGH Investigators: Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 365: 2255-2267, 2011
7. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators: Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl JMed 367: 2089-2099, 2012
8. Annema W, Tietge UJ: Regulation of reverse cholesterol transport-a comprehensive appraisal of available animal studies. Nutr Metab (Lond) 9: 25, 2012
9. Lewis GF, Rader DJ: New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 96: 1221-1232, 2005
10. Nijstad N, Gautier T, Briand F, Rader DJ, Tietge UJ: Biliary sterol secretion is required for functional in vivo reverse cholesterol transport in mice. Gastroenterology 140: 1043-1051, 2011
11. Abecassis M, Bartlett ST, Collins AJ, Davis CL, Delmonico FL, Friedewald JJ, Hays R, Howard A, Jones E, Leichtman AB, Merion RM, Metzger RA, Pradel F, Schweitzer EJ, Velez RL, Gaston RS: Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin J AmSocNephrol 3: 471-480, 2008
12. Ortiz A, Covic A, Fliser D, Fouque D, Goldsmith D, Kanbay M, Mallamaci F, Massy ZA, Rossignol P, Vanholder R,Wiecek A, Zoccali C, London GM; Board of the EURECA-m Working Group of ERA-EDTA: Epidemiology, contributors to, and clinical trials of mortality risk in chronic kidney failure. Lancet 383: 1831-1843, 2014
13. Meier-Kriesche HU, Schold JD, Srinivas TR, Reed A, Kaplan B: Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. Am J Transplant 4: 1662-1668, 2004
14. Oterdoom LH, de Vries AP, van Ree RM, Gansevoort RT, van Son WJ, van der Heide JJ, Navis G, de Jong PE, Gans RO, Bakker SJ: N-terminal pro-B-type natriuretic peptide and mortality in renal transplant recipients versus the general population. Transplantation 87: 1562-1570, 2009
15. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D: Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 342: 605-612, 2000
16. Mitchell RN, Libby P: Vascular remodeling in transplant vasculopathy. Circ Res 100: 967-978, 2007
17. Nankivell BJ, Chapman JR: Chronic allograft nephropathy: current concepts and future directions. Transplantation 81: 643-654, 2006
18. Colvin RB: Pathology of chronic humoral rejection. Contrib Nephrol 162: 75-86, 2009
19. Thaunat O: Humoral immunity in chronic allograft rejection: puzzle pieces come together. Transpl Immunol 26: 101-106, 2012
20. Yates PJ, Nicholson ML: The aetiology and pathogenesis of chronic allograft nephropathy. Transpl Immunol 16: 148-157, 2006
21. Paul LC: Chronic allograft nephropathy: An update. Kidney Int 56: 783-793, 1999
22. Triolo M, Annema W, Dullaart RP, Tietge UJ: Assessing the functional properties of high-density lipoproteins: an emerging concept in cardiovascular research. Biomarkers Med 7: 457-472, 2013
23. Ansell BJ, Fonarow GC, Fogelman AM: The paradox of dysfunctional high-density lipoprotein. Curr Opin Lipidol 18: 427-434, 2007
24. Sviridov D, Mukhamedova N, Remaley AT, Chin-Dusting J, Nestel P: Antiatherogenic functionality of high density lipoprotein: how much versus how good. J Atheroscler Thromb 15: 52-62, 2008
25. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl JMed 364: 127-135, 2011
26. Li XM, Tang WH,Mosior MK, Huang Y,Wu Y,MatterW, Gao V, Schmitt D, Didonato JA, Fisher EA, Smith JD, Hazen SL: Paradoxical association of enhanced cholesterol efflux with increased incident cardiovascular risks. Arterioscler Thromb Vasc Biol 33: 1696-1705, 2013
27. Rohatgi A, Khera A, Berry JD,Givens EG, Ayers CR,Wedin KE,Neeland IJ, Yuhanna IS, Rader DR, de Lemos JA, Shaul PW: HDL cholesterol efflux capacity and incident cardiovascular events. N Engl J Med 371: 2383-2393, 2014
28. Kopecky C, Haidinger M, Birner-Grünberger R, Darnhofer B, Kaltenecker CC, Marsche G, Holzer M, Weichhart T, Antlanger M, Kovarik JJ, Werzowa J, Hecking M, Säemann MD: Restoration of renal function does not correct impairment of uremic HDL properties. J Am Soc Nephrol 26: 565-575, 2015
29. Jardine AG, Gaston RS, Fellstrom BC, Holdaas H: Prevention of cardiovascular disease in adult recipients of kidney transplants. Lancet 378: 1419-1427, 2011
30. Israni AK, Snyder JJ, Skeans MA, Peng Y, Maclean JR, Weinhandl ED, Kasiske BL; PORT Investigators: Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant 10: 338-353, 2010
31. Mark PB, Johnston N, Groenning BA, Foster JE, Blyth KG, Martin TN, Steedman T, Dargie HJ, Jardine AG: Redefinition of uremic cardiomyopathy by contrast-enhanced cardiac magnetic resonance imaging. Kidney Int 69: 1839-1845, 2006
32. Solez K, Racusen LC, Abdulkareem F, Kemeny E, von Willebrand E, Truong LD: Adhesion molecules and rejection of renal allografts. Kidney Int 51: 1476-1480, 1997
33. Cockerill GW, Rye KA, Gamble JR, Vadas MA, Barter PJ: High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15: 1987-1994, 1995
34. Kasiske BL, Vazquez MA, Harmon WE, Brown RS, Danovitch GM, Gaston RS, Roth D, Scandling JD, Singer GG; American Society of Transplantation: Recommendations for the outpatient surveillance of renal transplant recipients. J Am Soc Nephrol 11[Suppl 15]: S1-S86, 2000
35. van Ree RM, de Vries AP, Oterdoom LH, The TH, Gansevoort RT, Homan van der Heide JJ, van SonWJ, Ploeg RJ, de Jong PE, Gans RO, Bakker SJ: Abdominal obesity and smoking are important determinants of C-reactive protein in renal transplant recipients. Nephrol Dial Transplant 20: 2524-2531, 2005
36. ZelleDM, Corpeleijn E, van Ree RM, Stolk RP, van der Veer E, Gans RO, Homan van der Heide JJ, Navis G, Bakker SJ: Markers of the hepatic component of the metabolic syndrome as predictors of mortality in renal transplant recipients. Am J Transplant 10: 106-114, 2010
37. Sinkeler SJ, Zelle DM, Homan van der Heide JJ, Gans RO, Navis G, Bakker SJ: Endogenous plasma erythropoietin, cardiovascular mortality and all-cause mortality in renal transplant recipients. Am J Transplant 12: 485-491, 2012
38. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106: 3143-3421, 2002
39. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 31[Suppl 1]: S55-S60, 2008
40. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 26[Suppl 1]: S5-S20, 2003
41. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18: 499-502, 1972
42. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function fromfasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419, 1985
43. de Leeuw K, Sanders JS, Stegeman C, Smit A, Kallenberg CG, Bijl M: Accelerated atherosclerosis in patients with Wegener's granulomatosis. Ann Rheum Dis 64: 753-759, 2005
44. Dullaart RP, Annema W, de Boer JF, Tietge UJ: Pancreatic b-cell function relates positively to HDL functionality in well-controlled type 2 diabetes mellitus. Atherosclerosis 222: 567-573, 2012
45. Kappelle PJ, de Boer JF, Perton FG, AnnemaW, de Vries R, Dullaart RP, Tietge UJ: Increased LCAT activity and hyperglycaemia decrease the antioxidative functionality of HDL. Eur J Clin Invest 42: 487-495, 2012
46. Mulder DJ, de Boer JF, Graaff R, de Vries R, Annema W, Lefrandt JD, Smit AJ, Tietge UJ, Dullaart RP: Skin autofluorescence is inversely related to HDL anti-oxidative capacity in type 2 diabetes mellitus. Atherosclerosis 218: 102-106, 2011
47. Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ: The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J AmColl Cardiol 58: 2068-2075, 2011
48. Annema W, Nijstad N, Tölle M, de Boer JF, Buijs RV, Heeringa P, van der Giet M, Tietge UJ: Myeloperoxidase and serum amyloid A contribute to impaired in vivo reverse cholesterol transport during the acute phase response but not group IIA secretory phospholipase A(2). J Lipid Res 51: 743-754, 2010